THC butanenitrile oxime (Tetrahydrocannaboxime, THCO) is a drug which is a cannabinoid receptor agonist. The isomer Δ8-THC butanenitrile oxime was originally synthesised by the research team led by Dr Alexandros Makriyannis in 2018 as a shorter lasting analogue of THC with a readily metabolized oxime link forming part of the side chain, allowing it to be more easily broken down by the body and thus shortening its duration of action. Subsequently it has appeared as a designer drug, initially in Germany and Russia, with both the Δ8 and Δ9 isomers being reported, sometimes with the active (6aR,10aR) trans enantiomer in a racemic mix with the inactive (6aS,10aS) trans enantiomer, and/or as a mixture of the E- and Z-isomeric oximes, presumably as a result of poorly controlled synthesis. It has been marketed as "THC oxime" or "THCO" which may cause confusion with O-acetyl-THC (commonly sold as "THC-O"), and has sometimes been misrepresented as a semi-synthetic product, even though unlike O-acetyl-THC, the published synthesis routes for THC butanenitrile oxime are entirely synthetic and do not originate from cannabidiol or other natural products extracted from Cannabis plant material. Both the Δ8 and Δ9 isomers of THC butanenitrile oxime have been added to the controlled drug list in several jurisdictions such as Hungary and Turkey.18 ÚJ SZER KERÜL TILTÓLISTÁRA: DE ELÉG-E A TILTÁS?Társadalmi egyeztetés az új pszichoaktív anyagok szabályozásáról.BAZI MADDELERİN 2313 SAYILI UYUŞTURUCU MADDELERİN MURAKABESİ HAKKINDA KANUN HÜKÜMLERİNE TABİ TUTULMASI HAKKINDA KARAR. Karar Sayısı: 11684. 31.08.2026 Tarih ve 33356 Sayılı R.G.
See also 1'-Dimethyl-Δ9-THCH 2-Allyl-Δ8-THC-O-acetate 2-Cl-HHC Adamantyl-HHC AM-7438 JWH-138
References